A Phase 1b Open Label Positron Emission Tomography Study to Assess Changes in Abdominal [11C]AZ14132516 Uptake Following Administration of Single and Repeat Doses of AZD7798 to Healthy Participants and Patients With Crohn's Disease
Latest Information Update: 30 Sep 2025
At a glance
- Drugs AZ 14132516 (Primary) ; AZD 7798 (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 27 Aug 2025 Number of arms changed from 1 to 6. Experimental arms: Panel 2, Panel 3, Panel 4, Panel 5 and Panel 6 added to study protocol. Primary and secondary outcome measure updated.
- 21 Nov 2024 Status changed from active, no longer recruiting to completed.
- 26 Sep 2024 Planned End Date changed from 16 Sep 2024 to 11 Oct 2024.